Share on StockTwits

Regeneron Pharmaceuticals (NASDAQ:REGN) Chairman P Roy Vagelos sold 8,028 shares of the company’s stock in a transaction dated Wednesday, August 13th. The shares were sold at an average price of $340.01, for a total value of $2,729,600.28. Following the completion of the transaction, the chairman now directly owns 248,540 shares of the company’s stock, valued at approximately $84,506,085. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Several analysts have recently commented on the stock. Analysts at RBC Capital raised their price target on shares of Regeneron Pharmaceuticals from $349.00 to $373.00 in a research note on Wednesday, August 6th. They now have an “outperform” rating on the stock. Separately, analysts at Roth Capital reiterated a “buy” rating on shares of Regeneron Pharmaceuticals in a research note on Tuesday, August 5th. Finally, analysts at Deutsche Bank raised their price target on shares of Regeneron Pharmaceuticals from $410.00 to $425.00 in a research note on Tuesday, August 5th. They now have a “buy” rating on the stock. Five research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $345.94.

Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) traded up 1.36% on Thursday, hitting $347.74. The stock had a trading volume of 566,565 shares. Regeneron Pharmaceuticals has a 1-year low of $227.64 and a 1-year high of $352.49. The stock has a 50-day moving average of $314.4 and a 200-day moving average of $308.0. The company has a market cap of $34.910 billion and a P/E ratio of 97.63.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Tuesday, August 5th. The company reported $2.47 EPS for the quarter, beating the Thomson Reuters consensus estimate of $2.30 by $0.17. The company had revenue of $666.00 million for the quarter, compared to the consensus estimate of $647.99 million. During the same quarter in the prior year, the company posted $1.73 earnings per share. The company’s quarterly revenue was up 45.4% on a year-over-year basis. Analysts expect that Regeneron Pharmaceuticals will post $10.08 EPS for the current fiscal year.

Regeneron Pharmaceuticals, Inc (NASDAQ:REGN) is an integrated biopharmaceutical company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.